Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02116777 · ClinicalTrials.gov registry record · Phase 1
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02116777: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT02116777 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02116777, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of talazoparib and temozolomide and to see how well they work in treating younger patients with tumors that have not responded to previous treatment (refractory) or have come back (recurrent). Talazoparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving talazoparib together with temozolomide may work better in treating younger patients with refractory or recurrent malignancies.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Temozolomide
- DRUG Talazoparib
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-05-16 |
| Est. Completion | 2018-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02116777
The ClinicalTrials.gov registry entry for NCT02116777 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02116777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02116777 about?
NCT02116777 is a clinical study titled "Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies". This phase I/II trial studies the side effects and best dose of talazoparib and temozolomide and to see how well they work in treating younger patients with tumors that have not responded to previous treatment (refractory) or have come back (recurrent). Talazoparib may stop the growth of cancer cell...
What is the current status of trial NCT02116777?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2014-05-16. Estimated completion is 2018-12-31.
What interventions are being tested in trial NCT02116777?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Temozolomide (DRUG), Talazoparib (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02116777?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.